metoclopramide has been researched along with Gastric Stasis in 58 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We identified 28 studies assessing AEs experienced by patients treated for gastroparesis with domperidone and metoclopramide; 22 studies contributed data to the meta-analyses." | 9.41 | Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis. ( Bennett, D; Betts, M; Fahrbach, K; Huh, SY; Junqueira, DR; Neupane, B, 2023) |
| "Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not in men, with diabetes." | 9.20 | Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study. ( Carlson, MR; Gonyer, D; Parkman, HP, 2015) |
| "To observe the clinical effects of acupoint injection of metoclopramide for postsurgical gastroparesis syndrome (PGS)." | 9.19 | [Observation on therapeutic effects of acupoint injection of metoclopramide for postsurgical gastroparesis syndrome]. ( Huang, XK; Jiang, J; Luo, Y; Wan, L; Wang, L; Zhang, CN, 2014) |
| "Metoclopramide nasal spray offers better symptom control than metoclopramide oral tablet in diabetic patients with symptoms of gastroparesis." | 9.19 | Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. ( Carlson, MR; Gonyer, D; Parkman, HP, 2014) |
| "Domperidone and metoclopramide effectively reduce the symptoms of diabetic gastroparesis; CNS side effects are more pronounced with metoclopramide." | 9.09 | A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. ( Abell, T; Barnett, J; Koch, K; Patterson, D; Rothstein, R, 1999) |
| "The risk of tardive dyskinesia due to metoclopramide is far below approximated numbers in treatment guidelines." | 9.01 | Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. ( Al-Saffar, A; Hellström, PM; Lennernäs, H, 2019) |
| "To review the safety and efficacy of chronic metoclopramide for diabetic gastroparesis." | 8.82 | Chronic metoclopramide therapy for diabetic gastroparesis. ( Lata, PF; Pigarelli, DL, 2003) |
| "The risks of weight gain that accompany the administration of metoclopramide are discussed, as well as the postulated etiology and psychological implications for the patient." | 7.72 | Metoclopramide and unintended weight gain. ( Sansone, LA; Sansone, RA, 2003) |
| " Erythromycin is associated with adverse reactions, including corrected QT interval prolongation and cytochrome P450 3A4 isoenzyme inhibition." | 5.72 | Safe Use of Erythromycin For Refractory Gastroparesis After Small Bowel Transplantation. ( Cruz, RJ; Humar, A; Poloyac, K; Roberts, M; Stein, W, 2022) |
| "We identified 28 studies assessing AEs experienced by patients treated for gastroparesis with domperidone and metoclopramide; 22 studies contributed data to the meta-analyses." | 5.41 | Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis. ( Bennett, D; Betts, M; Fahrbach, K; Huh, SY; Junqueira, DR; Neupane, B, 2023) |
| "Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not in men, with diabetes." | 5.20 | Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study. ( Carlson, MR; Gonyer, D; Parkman, HP, 2015) |
| "Metoclopramide nasal spray offers better symptom control than metoclopramide oral tablet in diabetic patients with symptoms of gastroparesis." | 5.19 | Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. ( Carlson, MR; Gonyer, D; Parkman, HP, 2014) |
| "To observe the clinical effects of acupoint injection of metoclopramide for postsurgical gastroparesis syndrome (PGS)." | 5.19 | [Observation on therapeutic effects of acupoint injection of metoclopramide for postsurgical gastroparesis syndrome]. ( Huang, XK; Jiang, J; Luo, Y; Wan, L; Wang, L; Zhang, CN, 2014) |
| "Domperidone and metoclopramide effectively reduce the symptoms of diabetic gastroparesis; CNS side effects are more pronounced with metoclopramide." | 5.09 | A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. ( Abell, T; Barnett, J; Koch, K; Patterson, D; Rothstein, R, 1999) |
| " the proportional cumulative area under the curve of paracetamol) was utilized in diabetic patients in order to detect both gastroparesis and the influence of metoclopramide, a known prokinetic drug, on this condition." | 5.08 | The proportional cumulative area under the curve of paracetamol used as an index of gastric emptying in diabetic patients with symptoms of gastroparesis. ( Moncrieff, J; Snyman, JR; Sommers, DK; van Wyk, M, 1995) |
| "The risk of tardive dyskinesia due to metoclopramide is far below approximated numbers in treatment guidelines." | 5.01 | Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. ( Al-Saffar, A; Hellström, PM; Lennernäs, H, 2019) |
| "A PubMed search was performed using search terms including gastroparesis, gastric retention, gastric emptying, accommodation, manometry, prokinetics, antiemetics, metoclopramide, domperidone, erythromycin, botulinum toxin, gastric pacing." | 4.84 | Review article: The diagnosis and management of gastroparesis. ( Haans, JJ; Masclee, AA, 2007) |
| "Metoclopramide, the only drug approved by the FDA for treatment of diabetic gastroparesis, but used off-label for a variety of other gastrointestinal indications, has many potentially troublesome adverse neurologic effects, particularly movement disorders." | 4.83 | Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. ( Jankovic, J; Pasricha, PJ; Pehlivanov, N; Sugumar, A, 2006) |
| "To review the safety and efficacy of chronic metoclopramide for diabetic gastroparesis." | 4.82 | Chronic metoclopramide therapy for diabetic gastroparesis. ( Lata, PF; Pigarelli, DL, 2003) |
| "For the drug treatment of gastroparesis, domperidone, metoclopramide and cisapride may be prescribed as prokinetics." | 4.80 | [Treatment of severely delayed gastric emptying]. ( Gooszen, HG; Samsom, M, 2000) |
| " Metoclopramide was administered for the treatment of gastroparesis." | 4.79 | Sinus arrest after administration of intravenous metoclopramide. ( Cruz-Flores, S; Gomez, CR; Malkoff, MD; Myles, GL; Ponzillo, JJ, 1995) |
| "This case report describes a patient, who presented with extrapyramidal side effects to the treatment with metoclopramide, which is used as an antiemetic, for gastroparesis and reflux." | 3.91 | [Metoclopramide-induced respiratory dyskinesia]. ( Lange, P; Vorre, MM, 2019) |
| " Submissions related to metoclopramide by far exceeded reports about other agents and mostly described tardive dyskinesia or other neurological concerns." | 3.85 | From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis. ( Bielefeldt, K, 2017) |
| "8% of patients received metoclopramide for gastroparesis, compared with 23." | 3.79 | The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. ( Deepak, P; Devi, R; Du, H; Ehrenpreis, ED; Leikin, JB; Sifuentes, H, 2013) |
| "To determine associations of clinical and pharmacogenetic parameters with response and side effects to metoclopramide in patients with upper gastrointestinal symptoms suggestive of gastroparesis." | 3.78 | Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. ( Gaughan, J; Jacobs, M; Krynetskiy, E; Mishra, A; Parkman, HP; Pathikonda, M; Sachdeva, P, 2012) |
| "The risks of weight gain that accompany the administration of metoclopramide are discussed, as well as the postulated etiology and psychological implications for the patient." | 3.72 | Metoclopramide and unintended weight gain. ( Sansone, LA; Sansone, RA, 2003) |
| "Gastroparesis is a functional gastrointestinal disorder that more commonly affects women, with most cases being diagnosed during childbearing age." | 3.01 | Gastroparesis in pregnancy. ( Min, YW; Moosavi, S; Rezaie, A; Wong, M, 2023) |
| "Gastroparesis is a neuromuscular disorder of the upper gastrointestinal tract." | 3.01 | Pharmacologic treatment of gastroparesis: What is (still) on the horizon? ( Pohl, D; Schweckendiek, D, 2023) |
| "Diabetic gastroparesis is defined as delayed gastric emptying without mechanical obstruction in the setting of diabetes." | 2.72 | Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. ( Baker, C; Petri, M; Rasouli, N; Singh, I; Underkofler, C, 2021) |
| "Gastroparesis is a chronic motility disorder that leads to delayed gastric emptying and negatively impacts morbidity, mortality, and quality of life." | 2.49 | Gastroparesis: what is the current state-of-the-art for evaluation and medical management? What are the results? ( Lee, A, 2013) |
| "During childhood, gastroparesis is quite rare, and is mostly seen in preterm infants, with either immaturity of the gastrointestinal tract, or when allergic to cow's milk protein." | 2.42 | Current pharmacological treatment of gastroparesis. ( Hauser, B; Salvatore, S; Vandenplas, Y, 2004) |
| " The appropriate use of prokinetic agents in these groups requires an understanding of the unique dosage considerations that may be necessary to ensure safe, effective therapy." | 2.39 | Use of prokinetic agents in special populations. ( Horn, JR, 1996) |
| " Erythromycin is associated with adverse reactions, including corrected QT interval prolongation and cytochrome P450 3A4 isoenzyme inhibition." | 1.72 | Safe Use of Erythromycin For Refractory Gastroparesis After Small Bowel Transplantation. ( Cruz, RJ; Humar, A; Poloyac, K; Roberts, M; Stein, W, 2022) |
| "Biopsy revealed a pulmonary squamous cell carcinoma, which was inoperable." | 1.62 | Gastrointestinal dysmotility in a patient with advanced lung cancer: paraneoplastic or drug-induced? ( Dias, RF; Diniz, MML; Nobre, VA; Santos, BC, 2021) |
| "Fatigue was reported by 93 % of patients." | 1.38 | Fatigue: a prevalent symptom in gastroparesis. ( Cherian, D; Paladugu, S; Parkman, HP; Pathikonda, M, 2012) |
| "Metoclopramide has the greatest evidence for efficacy followed by phenothiazines and tropisetron." | 1.36 | Nausea and vomiting in advanced cancer. ( Ang, SK; Davis, MP; Shoemaker, LK, 2010) |
| "Gastroparesis is a recognized cause of these symptoms in non-transplant patients but less is known about patients who undergo BMT." | 1.31 | Gastroparesis following bone marrow transplantation. ( Eagle, DA; Gian, V; Lauwers, GY; Manivel, JC; Mastin, S; Moreb, JS; Wingard, JR, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (10.34) | 18.2507 |
| 2000's | 19 (32.76) | 29.6817 |
| 2010's | 20 (34.48) | 24.3611 |
| 2020's | 13 (22.41) | 2.80 |
| Authors | Studies |
|---|---|
| Camilleri, M | 4 |
| Moosavi, S | 1 |
| Min, YW | 1 |
| Wong, M | 1 |
| Rezaie, A | 1 |
| Junqueira, DR | 1 |
| Bennett, D | 1 |
| Huh, SY | 1 |
| Fahrbach, K | 1 |
| Neupane, B | 1 |
| Betts, M | 1 |
| Schweckendiek, D | 1 |
| Pohl, D | 1 |
| Asha, MZ | 1 |
| Khalil, SFH | 1 |
| Usai-Satta, P | 1 |
| Bellini, M | 1 |
| Morelli, O | 1 |
| Geri, F | 1 |
| Lai, M | 1 |
| Bassotti, G | 1 |
| Petri, M | 1 |
| Singh, I | 1 |
| Baker, C | 1 |
| Underkofler, C | 1 |
| Rasouli, N | 1 |
| Dias, RF | 1 |
| Diniz, MML | 1 |
| Santos, BC | 1 |
| Nobre, VA | 1 |
| Gajendran, M | 1 |
| Sarosiek, I | 1 |
| McCallum, R | 1 |
| Lacy, BE | 1 |
| Cangemi, DJ | 1 |
| Cruz, RJ | 1 |
| Poloyac, K | 1 |
| Roberts, M | 1 |
| Stein, W | 1 |
| Humar, A | 1 |
| Kuo, B | 1 |
| Mahadeva, S | 1 |
| Bielefeldt, K | 1 |
| Kim, GH | 1 |
| Jung, KW | 1 |
| Vorre, MM | 1 |
| Lange, P | 1 |
| Al-Saffar, A | 1 |
| Lennernäs, H | 1 |
| Hellström, PM | 1 |
| Shakhatreh, M | 1 |
| Jehangir, A | 1 |
| Malik, Z | 1 |
| Parkman, HP | 5 |
| Ehrenpreis, ED | 1 |
| Deepak, P | 1 |
| Sifuentes, H | 1 |
| Devi, R | 1 |
| Du, H | 1 |
| Leikin, JB | 1 |
| Lee, A | 1 |
| Janssen, P | 1 |
| Harris, MS | 1 |
| Jones, M | 1 |
| Masaoka, T | 1 |
| Farré, R | 1 |
| Törnblom, H | 1 |
| Van Oudenhove, L | 1 |
| Simrén, M | 1 |
| Tack, J | 1 |
| Carlson, MR | 2 |
| Gonyer, D | 3 |
| Lankarani, K | 1 |
| Parkman, H | 1 |
| Carlson, M | 1 |
| Zhang, CN | 1 |
| Huang, XK | 1 |
| Luo, Y | 1 |
| Jiang, J | 1 |
| Wan, L | 1 |
| Wang, L | 1 |
| Acosta, A | 1 |
| Shakil, A | 1 |
| Church, RJ | 1 |
| Rao, SS | 1 |
| Bernstein, R | 1 |
| Ang, SK | 1 |
| Shoemaker, LK | 1 |
| Davis, MP | 1 |
| Sun, BM | 1 |
| Luo, M | 1 |
| Wu, SB | 1 |
| Chen, XX | 1 |
| Wu, MC | 1 |
| Cherian, D | 1 |
| Paladugu, S | 1 |
| Pathikonda, M | 2 |
| Shin, A | 1 |
| Mishra, A | 1 |
| Jacobs, M | 1 |
| Sachdeva, P | 1 |
| Gaughan, J | 1 |
| Krynetskiy, E | 1 |
| Lyday, WD | 1 |
| DiBaise, JK | 1 |
| Lata, PF | 1 |
| Pigarelli, DL | 1 |
| Sansone, RA | 1 |
| Sansone, LA | 1 |
| Bouras, EP | 1 |
| Scolapio, JS | 1 |
| Vandenplas, Y | 1 |
| Hauser, B | 1 |
| Salvatore, S | 1 |
| Tsuji, S | 1 |
| Hayashi, N | 1 |
| Kong, MF | 1 |
| Horowitz, M | 1 |
| Pasricha, PJ | 1 |
| Pehlivanov, N | 1 |
| Sugumar, A | 1 |
| Jankovic, J | 1 |
| Wollheim, FA | 1 |
| Akesson, A | 1 |
| Tarsy, D | 1 |
| Nagula, S | 1 |
| Schattner, M | 1 |
| Haans, JJ | 1 |
| Masclee, AA | 1 |
| Malkoff, MD | 1 |
| Ponzillo, JJ | 1 |
| Myles, GL | 1 |
| Gomez, CR | 1 |
| Cruz-Flores, S | 1 |
| Jia, B | 1 |
| van Wyk, M | 1 |
| Sommers, DK | 1 |
| Snyman, JR | 1 |
| Moncrieff, J | 1 |
| Horn, JR | 1 |
| Ross, EA | 1 |
| Koo, LC | 1 |
| Patterson, D | 1 |
| Abell, T | 1 |
| Rothstein, R | 1 |
| Koch, K | 1 |
| Barnett, J | 1 |
| Dumitrascu, DL | 1 |
| Weinbeck, M | 1 |
| Zaloga, GP | 1 |
| Marik, P | 1 |
| Samsom, M | 1 |
| Gooszen, HG | 1 |
| Eagle, DA | 1 |
| Gian, V | 1 |
| Lauwers, GY | 1 |
| Manivel, JC | 1 |
| Moreb, JS | 1 |
| Mastin, S | 1 |
| Wingard, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.[NCT02130622] | Phase 2 | 3 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Lack of recruitment) | ||
| A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Clinical Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Subjects With Gastroparesis[NCT00845858] | Phase 2 | 287 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Impact of Prokinetic Use After Emergency Intestinal Anastomosis on Short and long_term Clinical Outcome[NCT05290753] | 15 participants (Anticipated) | Interventional | 2022-01-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change from Baseline to Week 4 of the treatment period in the mGCSI-DD total score in Female subjects receiving metoclopramide nasal spray versus Female subjects receiving placebo.~The mGCSI-DD is a patient reported outcome measure of gastroparesis symptom severity composed of 4 individual symptoms (listed below) with each symptom graded on a scale from 0 (none) to 5 (very severe).~Nausea (feeling sick to your stomach as if you were going to vomit or throw up)~Early satiety (not able to finish a normal sized meal)~Bloating (feeling like you need to loosen clothes)~Upper abdominal pain (above the navel) The mGCSI-DD daily score is a mean of the 4 individual symptom scores. The total score is a mean of the daily scores for the observation period.~A mean change (improvement) of >1 category (for example, moderate to mild or severe to moderate) is considered to be clinically meaningful." (NCT00845858)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Female-Metoclopramide Nasal Spray 10 mg | -1.2 |
| Female-Metoclopramide Nasal Spray 14 mg | -1.3 |
| Female-Placebo Nasal Spray | -0.8 |
"Change from Baseline to Week 4 of the treatment period in the mGCSI-DD total score in male and female subjects receiving metoclopramide nasal spray versus subjects receiving placebo.~The mGCSI-DD is a patient reported outcome measure of gastroparesis symptom severity composed of 4 individual symptoms (listed below) with each symptom graded on a scale from 0 (none) to 5 (very severe).~Nausea (feeling sick to your stomach as if you were going to vomit or throw up)~Early satiety (not able to finish a normal sized meal)~Bloating (feeling like you need to loosen clothes)~Upper abdominal pain (above the navel) The mGCSI-DD daily score is a mean of the 4 individual symptom scores. The total score is a mean of the daily scores for the observation period.~A mean change (improvement) of >1 category (for example, moderate to mild or severe to moderate) is considered to be clinically meaningful." (NCT00845858)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metoclopramide Nasal Spray 10 mg | -1.2 |
| Metoclopramide Nasal Spray 14 mg | -1.2 |
| Placebo Nasal Spray | -1.0 |
25 reviews available for metoclopramide and Gastric Stasis
| Article | Year |
|---|---|
Gastroparesis in pregnancy.
Topics: Female; Gastrointestinal Agents; Gastroparesis; Humans; Metoclopramide; Pregnancy | 2023 |
Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis.
Topics: Adult; Child; Domperidone; Dopamine Antagonists; Gastroparesis; Humans; Metoclopramide | 2023 |
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Topics: Gastroparesis; Humans; Metoclopramide | 2023 |
Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials.
Topics: Antiemetics; Cisapride; Diabetes Complications; Domperidone; Gastric Emptying; Gastrointestinal Agen | 2019 |
Gastroparesis: New insights into an old disease.
Topics: Antidepressive Agents, Tricyclic; Antiemetics; Cannabinoids; Capsule Endoscopy; Electric Stimulation | 2020 |
Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists.
Topics: Diabetes Mellitus; Diabetic Neuropathies; Gastric Emptying; Gastroparesis; Humans; Metoclopramide; Q | 2021 |
Metoclopramide nasal spray (Gimoti) for diabetic gastroparesis.
Topics: Clinical Trials as Topic; Diabetes Mellitus; Dopamine D2 Receptor Antagonists; Gastroparesis; Humans | 2021 |
Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults.
Topics: Diabetes Mellitus; Diabetic Neuropathies; Gastroparesis; Humans; Metoclopramide; Nasal Sprays; Treat | 2021 |
[Vomiting].
Topics: Antineoplastic Agents; Feeding Behavior; Gastric Emptying; Gastritis; Gastroparesis; Humans; Metoclo | 2017 |
Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited.
Topics: Antiemetics; Dopamine D2 Receptor Antagonists; Gastroparesis; Humans; Metoclopramide; Risk Factors; | 2019 |
Metoclopramide for the treatment of diabetic gastroparesis.
Topics: Diabetes Complications; Dopamine D2 Receptor Antagonists; Gastric Emptying; Gastroparesis; Humans; M | 2019 |
Gastroparesis: what is the current state-of-the-art for evaluation and medical management? What are the results?
Topics: Botulinum Toxins; Combined Modality Therapy; Diet Therapy; Domperidone; Erythromycin; Gastrointestin | 2013 |
The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis.
Topics: Cisapride; Diabetes Mellitus, Type 2; Domperidone; Erythromycin; Gastric Emptying; Gastrointestinal | 2013 |
Prokinetics in gastroparesis.
Topics: Gastrointestinal Agents; Gastrointestinal Motility; Gastroparesis; Humans; Metoclopramide; Off-Label | 2015 |
Gastrointestinal complications of diabetes.
Topics: Algorithms; Antiemetics; Diabetes Complications; Fatty Liver; Gastric Emptying; Gastroparesis; Human | 2008 |
Chronic metoclopramide therapy for diabetic gastroparesis.
Topics: Antiemetics; Diabetes Complications; Drug Administration Schedule; Gastroparesis; Humans; Metoclopra | 2003 |
Gastric motility disorders: management that optimizes nutritional status.
Topics: Antiemetics; Diet; Dumping Syndrome; Gastrointestinal Agents; Gastrointestinal Motility; Gastropares | 2004 |
Current pharmacological treatment of gastroparesis.
Topics: Adult; Child; Cisapride; Domperidone; Erythromycin; Gastrointestinal Agents; Gastroparesis; Humans; | 2004 |
[Digestive disorders in diabetic patients].
Topics: Autonomic Nervous System; Diabetes Complications; Diagnostic Imaging; Gastrectomy; Gastric Acidity D | 2005 |
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide.
Topics: Dopamine Antagonists; Drug Utilization Review; Gastroparesis; Humans; Metoclopramide; Movement Disor | 2006 |
Review article: The diagnosis and management of gastroparesis.
Topics: Diet; Domperidone; Dopamine Antagonists; Erythromycin; Gastric Emptying; Gastrointestinal Agents; Ga | 2007 |
Sinus arrest after administration of intravenous metoclopramide.
Topics: Arrhythmia, Sinus; Autonomic Nervous System Diseases; Female; Gastroparesis; Humans; Injections, Int | 1995 |
Use of prokinetic agents in special populations.
Topics: Age Factors; Cisapride; Drug Interactions; Gastroesophageal Reflux; Gastrointestinal Agents; Gastroi | 1996 |
Promotility agents in the intensive care unit.
Topics: Cisapride; Enteral Nutrition; Erythromycin; Gastrointestinal Agents; Gastrointestinal Motility; Gast | 2000 |
[Treatment of severely delayed gastric emptying].
Topics: Cisapride; Diagnosis, Differential; Digestive System Surgical Procedures; Domperidone; Dyspepsia; El | 2000 |
7 trials available for metoclopramide and Gastric Stasis
| Article | Year |
|---|---|
Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiem | 2014 |
[Observation on therapeutic effects of acupoint injection of metoclopramide for postsurgical gastroparesis syndrome].
Topics: Acupuncture Points; Adult; Aged; Female; Gastroparesis; Humans; Male; Metoclopramide; Middle Aged; P | 2014 |
Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Antiemetics; Diabetes Complications; Double-Bli | 2015 |
Acupuncture versus metoclopramide in treatment of postoperative gastroparesis syndrome in abdominal surgical patients: a randomized controlled trial.
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Female; Gastroparesis; Humans; Male; Metoclopramide; | 2010 |
The proportional cumulative area under the curve of paracetamol used as an index of gastric emptying in diabetic patients with symptoms of gastroparesis.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Diabetes Mellitus, Type 1; Diabetic Neuropathi | 1995 |
A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis.
Topics: Adult; Aged; Antiemetics; Diabetes Mellitus, Type 1; Domperidone; Dopamine Antagonists; Double-Blind | 1999 |
Domperidone versus metoclopramide in the treatment of diabetic gastroparesis.
Topics: Adult; Aged; Diabetes Complications; Domperidone; Double-Blind Method; Female; Gastric Emptying; Gas | 2000 |
26 other studies available for metoclopramide and Gastric Stasis
| Article | Year |
|---|---|
Beyond Metoclopramide for Gastroparesis.
Topics: Antiemetics; Gastric Emptying; Gastroparesis; Humans; Metoclopramide | 2022 |
Gastrointestinal dysmotility in a patient with advanced lung cancer: paraneoplastic or drug-induced?
Topics: Aged; Antiemetics; Carcinoma, Squamous Cell; Constipation; Gastrointestinal Agents; Gastrointestinal | 2021 |
Controversies in Gastroparesis: Discussing the Sticky Points.
Topics: Abdominal Pain; Antiemetics; Chronic Disease; Diabetes Complications; Diagnosis, Differential; Diagn | 2021 |
Safe Use of Erythromycin For Refractory Gastroparesis After Small Bowel Transplantation.
Topics: Cytochrome P-450 Enzyme System; Erythromycin; Female; Gastroparesis; Humans; Metoclopramide; Tacroli | 2022 |
Editorial: finding the ideal prokinetic for gastroparesis-we are not there yet. Authors' reply.
Topics: Gastric Emptying; Gastroparesis; Humans; Metoclopramide | 2021 |
Editorial: finding the ideal prokinetic for gastroparesis-we are not there yet.
Topics: Gastric Emptying; Gastroparesis; Humans; Metoclopramide | 2021 |
From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antiemetics; Databases, Factual; Deglutition D | 2017 |
[Metoclopramide-induced respiratory dyskinesia].
Topics: Antiemetics; Dyskinesia, Drug-Induced; Gastroparesis; Humans; Metoclopramide | 2019 |
The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits.
Topics: Adverse Drug Reaction Reporting Systems; Domperidone; Dopamine Antagonists; Drug Labeling; Gastropar | 2013 |
Is metoclopramide nasal spray an acceptable alternative to its oral form?
Topics: Antiemetics; Diabetes Complications; Female; Gastroparesis; Humans; Male; Metoclopramide | 2014 |
Response to Dr. Lankarani.
Topics: Antiemetics; Diabetes Complications; Female; Gastroparesis; Humans; Male; Metoclopramide; Nasal Spra | 2014 |
Gastroparesis: what you should know.
Topics: Antiemetics; Diabetes Complications; Diet; Gastroparesis; Humans; Metoclopramide | 2008 |
Warnings on metoclopramide treatment.
Topics: Antiemetics; Diabetes Complications; Dopamine Antagonists; Gastroparesis; Metoclopramide | 2009 |
Nausea and vomiting in advanced cancer.
Topics: Algorithms; Antiemetics; Causality; Decision Trees; Drug Therapy, Combination; Evidence-Based Medici | 2010 |
Fatigue: a prevalent symptom in gastroparesis.
Topics: Adult; Diagnostic Self Evaluation; Domperidone; Dopamine Antagonists; Dyspepsia; Fatigue; Female; Ga | 2012 |
Lessons from pharmacogenetics and metoclopramide: toward the right dose of the right drug for the right patient.
Topics: Dopamine Antagonists; Female; Gastroparesis; Humans; Male; Metoclopramide; Polymorphism, Single Nucl | 2012 |
Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters.
Topics: Adult; Age Factors; Body Mass Index; Diabetes Mellitus; Dopamine Antagonists; Dose-Response Relation | 2012 |
Metoclopramide-stimulated gastric emptying scintigraphy: does it predict symptom response to prokinetic therapy in chronic gastroparesis?
Topics: Chronic Disease; Dopamine Antagonists; Dose-Response Relationship, Drug; Gastric Emptying; Gastroint | 2002 |
Metoclopramide and unintended weight gain.
Topics: Adult; Anorexia Nervosa; Antiemetics; Body Constitution; Body Image; Dose-Response Relationship, Dru | 2003 |
Diabetic gastroparesis.
Topics: Adult; Antiemetics; Diabetes Complications; Diet; Domperidone; Dopamine Agonists; Erythromycin; Fema | 2005 |
Management of intestinal involvement in systemic sclerosis.
Topics: Domperidone; Dopamine Antagonists; Gastrointestinal Agents; Gastroparesis; Humans; Indoles; Metoclop | 2007 |
Diabetic gastroparesis.
Topics: Diabetes Complications; Dopamine Antagonists; Dyskinesia, Drug-Induced; Gastroparesis; Humans; Metoc | 2007 |
Malignant gastroparesis: diagnostics and therapeutics.
Topics: Anti-Bacterial Agents; Antiemetics; Erythromycin; Gastroparesis; Humans; Metoclopramide; Neoplasms | 2007 |
[Drug therapy of gastrointestinal motility disorders].
Topics: Cisapride; Domperidone; Dyspepsia; Gastroesophageal Reflux; Gastroparesis; Humans; Metoclopramide; P | 1995 |
Improved nutrition after the detection and treatment of occult gastroparesis in nondiabetic dialysis patients.
Topics: Erythromycin; Female; Gastric Emptying; Gastroparesis; Humans; Kidney Failure, Chronic; Male; Metocl | 1998 |
Gastroparesis following bone marrow transplantation.
Topics: Adult; Antiemetics; Bone Marrow Transplantation; Case-Control Studies; Erythromycin; Female; Gastric | 2001 |